CAJ | 학술논문

目的研究参芪扶正注射液对血液系统恶性肿瘤化疗患者造血功能和免疫功能的影响. 方法 80例均处于初治诱导缓解治疗阶段的血液肿瘤患者,分为治疗组和对照组,治疗组在化疗的同时给予参芪扶正注射液250 mL/(g·d) ,共14天,对照组单用化疗,两组其他支持治疗相同.观察两组化疗后缓解率,化疗前后血常规、T淋巴细胞亚群(CD_3~+、CD_4~+、CD+4/CD_8~+)和B淋巴细胞(CD_3~- CD_(19)~+)的水平. 结果化疗后缓解率治疗组[90.0%(36/40)]与对照组[82.5%(33/40)]比较,差异无统计学意义(P>0.05);化疗后治疗组外周血白细胞计数和血红蛋白均高于对照组(P＜0.05);CD_3~+、CD_4~+及CD_4~+/CD_8~+水平均明显高于对照组(P＜0.05),CD_3~- CD_(19)~+ 两组比较差异无统计学意义. 结论参芪扶正注射液能减轻化疗对血液肿瘤患者骨髓造血功能的抑制,并能促进化疗患者骨髓造血功能的恢复;提高化疗患者的细胞免疫功能;改善血液肿瘤化疗患者的生活质量.
목적 연구삼기부정주사액대혈액계통악성종류화료환자조혈공능화면역공능적영향. 방법 80례균처우초치유도완해치료계단적혈액종류환자,분위치료조화대조조,치료조재화료적동시급여삼기부정주사액250 mL/(g·d) ,공14천,대조조단용화료,량조기타지지치료상동.관찰량조화료후완해솔,화료전후혈상규、T림파세포아군(CD_3~+、CD_4~+、CD+4/CD_8~+)화B림파세포(CD_3~- CD_(19)~+)적수평. 결과화료후완해솔치료조[90.0%(36/40)]여대조조[82.5%(33/40)]비교,차이무통계학의의(P>0.05);화료후치료조외주혈백세포계수화혈홍단백균고우대조조(P＜0.05);CD_3~+、CD_4~+급CD_4~+/CD_8~+수평균명현고우대조조(P＜0.05),CD_3~- CD_(19)~+ 량조비교차이무통계학의의. 결론삼기부정주사액능감경화료대혈액종류환자골수조혈공능적억제,병능촉진화료환자골수조혈공능적회복;제고화료환자적세포면역공능;개선혈액종류화료환자적생활질량.
Objective To investigate the effect of Shenqi Fuzheng Injection (SFI) for hemopoietic and immune function reconstruction in patients with hematologic malignancies (HM) after chemotherapy. Methods Eighty HM patients at remission inducing stage of initial treatment were randomly assigned to two groups,the treatment group treated with SFI (250 mL daily) plus chemotherapy and the control group only treated with chemotherapy for 14 days,with same supportive treatments administered to both. Levels of blood routine test,T lymphocyte subsets (CD_3~+,CD_4~+,CD_4~+/CD_8~+) and B lymphocyte subsets CD_3~- CD_(19)~+ were determined before and after treatment,and the remission rate was assessed after treatment. Results The remission rates in the two groups showed no significant difference [90% (36/40) vs 82.5% (33/40),P>0.05] statistically. Levels of peripheral leucocyte count and hemoglobin as well as levels of CD_3~+,CD_4~+,CD_4~+/CD_8~+ were significantly higher in the treatment group than in the control group (P＜0.05),but no significant difference was shown between groups in CD_3~- CD_(19)~+ level. Conclusion SFI can lighten the inhibition of chemotherapy on hemopoietic function of bone marrow,and promote its recovery,enhance the immune function,and improve the quality of life in patients with HM undergoing chemotherapy.